Agile therapeutics inc (AGRX)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Dec'13
Assets
Current assets:
Cash and cash equivalents

93,925

34,479

18,370

10,586

11,560

7,851

16,926

22,465

28,344

35,952

43,806

33,938

41,744

48,750

51,670

59,224

65,495

34,395

39,404

46,407

53,865

40,182

45,679

53,494

2,119

Prepaid expenses

672

840

1,316

178

378

607

731

200

633

762

1,161

525

2,525

2,768

3,094

2,073

3,034

3,690

1,260

817

495

804

1,369

-

146

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

661

-

Total current assets

94,597

35,319

19,686

10,764

11,938

8,458

17,657

22,665

28,977

36,714

44,967

34,463

44,269

51,518

54,764

61,297

68,529

38,085

40,665

47,224

54,360

40,986

47,049

54,155

2,266

Property and equipment, net

14,154

14,044

13,932

13,906

13,911

13,916

13,921

13,924

13,927

13,863

13,426

12,769

12,330

12,330

12,330

12,329

12,316

12,318

12,320

12,310

12,229

12,046

11,997

11,964

11,963

Right of use and other assets

136

177

-

-

-

18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right of use and other assets

-

-

214

250

284

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses, long-term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,751

1,751

1,677

1,678

1,677

-

-

Deferred financing costs, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

330

370

410

98

115

132

157

Other assets

-

-

-

-

-

-

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

Total assets

108,887

49,540

33,832

24,920

26,133

22,392

31,596

36,607

42,922

50,595

58,411

47,250

56,617

63,866

67,112

73,644

80,863

50,421

55,085

61,674

68,696

54,826

60,858

66,271

14,405

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

2,031

1,819

603

804

700

875

488

1,078

2,071

2,784

2,823

2,986

3,182

2,050

2,889

3,010

2,873

2,387

4,349

2,663

3,309

2,631

2,654

2,325

715

Accrued expenses

649

1,804

1,114

803

483

1,343

2,022

1,751

1,130

852

1,857

1,186

2,567

3,644

1,755

1,260

1,394

2,653

2,348

2,214

1,108

1,062

660

373

379

Lease liability, current portion

128

172

178

167

157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loan payable, current portion

-

-

-

-

-

-

5,905

7,525

9,090

10,607

6,190

5,981

5,780

5,104

3,486

5,568

3,929

2,336

-

-

-

5,003

3,559

2,151

5,105

Warrant liability

-

-

-

-

-

-

-

-

22

29

90

70

63

172

238

276

213

406

251

355

396

296

365

452

644

Total current liabilities

2,808

3,795

1,895

1,774

1,340

2,218

8,415

10,354

12,313

14,272

10,960

10,223

11,592

10,970

8,368

10,114

8,409

7,782

6,949

5,233

4,814

8,992

7,240

5,302

6,844

Long-term debt

15,472

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability, long-term

-

-

34

82

128

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loan payable, long-term

-

-

-

-

-

-

-

-

-

-

5,887

7,886

9,416

10,607

12,077

10,008

11,475

12,896

15,390

15,257

15,124

9,828

11,241

12,619

9,769

Total liabilities

18,280

3,795

-

-

-

2,218

-

-

-

14,272

-

-

-

21,577

-

-

-

-

-

-

-

-

-

-

-

Commitments and contingencies (Note 13)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders' equity
Preferred stock, $.0001 par value, authorized 10,000,000 shares; issued 0 shares outstanding at December 31, 2013 and September 30, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Common stock, $.0001 par value, 150,000,000 shares authorized, 87,213,212 and 69,810,305 issued and outstanding at March 31, 2020 and December 31, 2019, respectively

9

7

6

4

4

3

3

3

3

3

3

3

3

3

3

3

3

2

2

2

2

2

1

1

0

Additional paid-in capital

358,851

306,108

286,246

272,977

271,094

261,722

260,919

260,199

259,211

258,092

257,093

237,567

236,590

235,754

234,931

233,982

233,021

194,468

193,571

192,597

191,684

170,396

169,921

169,540

46,872

Accumulated deficit

-268,000

-260,370

-254,349

-249,917

-246,433

-241,551

-237,741

-233,949

-228,605

-221,772

-215,532

-208,429

-200,984

-193,468

-188,267

-180,463

-172,045

-164,727

-160,828

-151,416

-142,930

-134,392

-

-

-118,314

Accumulated deficit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

127,546

121,193

-

Total stockholders' equity

90,607

45,745

31,903

23,064

24,665

20,174

23,181

26,253

30,609

36,323

41,564

29,141

35,609

42,289

46,667

53,522

60,979

29,743

32,745

41,183

48,756

36,006

42,376

48,348

-71,441

Total liabilities and stockholders' equity

108,887

49,540

33,832

24,920

26,133

22,392

31,596

36,607

42,922

50,595

58,411

47,250

56,617

63,866

67,112

73,644

80,863

50,421

55,085

61,674

68,696

54,826

60,858

66,271

14,405